MAPT and Lewy body dementia: While the addition of novel ultra-sensitive assay of biomarkers related to AD (Aβ40, Aβ42, total tau) neurodegeneration (Nf-L) and LBD (α-synuclein) improved the detection accuracy of the DBT some, it is possible that the inclusion of other biomarkers could aid in the detection of DLB as well as the discrimination of DLB from other neurodegenerative diseases.